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Abstract
Background. Tracheobronchomalacia is the most common cause of congenital airway obstruction in infants. 
An alternative for surgical approach (aortopexy) can be metallic airway stents. Usually, they are not considered 
as a first choice because of the relatively high risk of complications. Recent years have brought encouraging 
reports of biodegradable stents applied in children.
Objectives. The aim of this study was to report our experience in the treatment of airway malacia using 
biodegradable stents.
Material and methods. Six polydioxanone (PDS), self-expanding custom-made stents (ELLA-CS) were 
implanted in 2 children: 3 in the patient with left main bronchus occlusion due to postpnemonectomy 
syndrome and 3 stents in the baby with tracheomalacia.
Results. Airway collapse was always relieved after stent expansion. Both patients needed repeated stent-
ing because of limited stent lifespan. All the stents were implanted without complications through a rigid 
bronchoscope. The baby with stented main bronchus died because of irreversible lung lesion.
Conclusions. This small study shows that biodegradable airway stents seem to be an attractive option 
in the treatment of tracheobronchomalacia in children. We consider this method to be safe, effective, re-
peatable, and reversible in small children with growing airways. As a time-buying procedure they can be 
especially useful in the treatment of tracheobronchomalacia.
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Introduction
Airway stenting in adults is a well-established thera-
peutic method for the treatment of benign and malignant 
tracheobronchial obstruction. Stents can be used in pre-
venting restenosis after airway reconstruction, lung trans-
plantation or in palliative therapy in non-resectable tu-
mors.1 In the long history of endoluminal airway support, 
the first stents to be invented were made of metal, later 
of plastic and then followed by mixed forms (hybrids).2 
Moreover, the  last 2 decades have brought new tech-
nologies and materials that have led to the introduction 
of biodegradable materials in thoracic surgery. Initially, 
biodegradable stents were used in esophageal, intestinal, 
biliary, urethral, and vascular stenosis.3–5 Finally, the idea 
was adapted for the treatment of airway obstruction.
In neonates and young children, we encounter 2 main 
types of pathologies: anatomical and dynamic airway ob-
structions. The former usually results from congenital tra-
cheal stenosis or concomitant vascular abnormalities, and 
the later type is represented by dynamic obstructions with 
bronchial or tracheal wall collapse. Although surgical treat-
ment is still the primary therapeutic option for patients with 
various types of congenital tracheal stenosis, in the second 
group with tracheobronchomalacia, stents could be an at-
tractive alternative. To date, the use of metal stents in neo-
nates has been limited due to numerous life-threatening 
local complications, such as tracheobronchial wall erosion, 
bleeding and severe mucosal tissue granulation with airway 
narrowing.6,7 In addition, most metal stents are permanent 
once inserted and cannot be replaced, which greatly limits 
their use in the developing airways of children.8
The emergence of biodegradable airway stents seems 
to have opened a new chapter in  the  treatment of dy-
namic types of airway obstruction in newborns and small 
children. The use of polydioxanon (PDS) stents has been 
recently reported in a growing number of small patient 
series with encouraging clinical results.9–12 Polydioxanon 
belongs to the family of biodegradable synthetic polymers 
and is widely used for the preparation of surgical sutures. 
As a monofilament fiber, it hardens binding parts of water, 
presents shape memory and degrades by random hydroly-
sis of its ester bonds with the mean biodegradation time 
between 12–15 weeks, proven in animal models.13,14
We  report our preliminary experience with the use 
of  bio-stents in  children in  the  treatment of tracheo-
bronchomalacia.
Material and methods
Six bio-stents were implanted in 2 infants. The pres-
ent clinical trial was approved by our Institutional Eth-
ics Committee. Parental informed consent was obtained 
before each procedure. Self-expanding PDS bio-stents 
were custom-made and delivered with the  introducer 
by the manufacturer (ELLA-CS, Hradec Králové, Czech 
Republic). The  decision regarding stenting was made 
by our multidisciplinary team: thoracic surgeons, pediatri-
cians and anesthetists. The sizes of the ordered stents were 
decided after initial rigid bronchoscopy in which we mea-
sured the diameter of the airway and estimated the length 
of stents. Each stent was delivered expanded in an airtight 
container and with a separately packed introducer. Imme-
diately before implantation, we manually pressed the stent 
and placed it on the introducer under a moveable sheath. 
All the bio-stents were implanted under general anesthesia 
through a rigid Karl Storz bronchoscope size 4.0. Expan-
sion of the stent was controlled using a small-size optics 
(diameter 1.3 mm; length 30.6 cm), which is longer than 
the bronchoscope, inserted along together with the intro-
ducer and positioned laterally. After implantation, we used 
the same longer optics or a small-size bronchofiberoscope 
for insertion inside the expanded stent to check the results 
and control both ends of the stent.
Results
Patient 1
A female newborn, twin delivered by a Cesarean section 
because of life-threatening asphyxia after 34 weeks of gesta-
tion, with birth body mass of 1,770 g, presented respiratory 
compromise since birth. Chest x-ray and CT scan revealed 
congenital cystic adenomatoid malformation (CCAM) af-
fecting the entire right lung. The patient needed an urgent 
right lobectomy in the neonatal period due to severe respi-
ratory distress and mass effect. The postsurgical course 
was uneventful. Six months after surgery, dyspnea appeared 
along with recurrent respiratory infections because of post-
pneumonectomy syndrome (PPS) with a severe rightward 
mediastinal shift and rightward left lung expansion. Me-
chanical ventilatory support with intubation was manda-
tory. Bronchoscopy showed an almost complete collapse 
of the left main bronchus with bronchial tree rotation (Fig. 1).
Postnatally, the baby had extensive cerebral infarction, 
so the therapeutic team together with the parents aban-
doned the idea of possible surgical correction with cardio-
pulmonary bypass and decided to use a bio-stent. A PDS 
stent 5 × 20 mm was implanted. After 2 days, the patient 
was extubated and control bronchofiberoscopy confirmed 
proper stent positioning and open bronchus. The sub-
sequent 2 stents were implanted after the  dissolution 
of the previous one, increasing the diameter to 6 mm and 
length to 25 mm, which corresponded to the increasing 
diameter of the airway. After implantation of the first 2 
stents, the patient stayed home in good general condition, 
gaining weight properly. After the 3rd stenting, the par-
ents refused further therapy. Upon their request, the baby 
was placed in the hospice, where she died 4 months after 
the last stent implantation.
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Patient 2
A male newborn twin delivered after 36 weeks of ges-
tation with a birth body mass of 2,100 g was operated 
on through left thoracotomy in the 1st day of life because 
of esophageal atresia.
After surgery, the  patient could not be weaned from 
ventilatory support for the first 5 months and later needed 
continuous positive airway pressure (CPAP). The child was 
discharged home, but subsequently needed emergency hos-
pitalization due to an episode of life-threatening asphyxia. 
Possible concomitant abnormalities, such as vascular ring, 
sling and complete tracheal rings had been previously ex-
cluded using CT scan in the referring hospital. The baby 
was referred to our center at the age of 6 months. On admis-
sion, bronchoscopy demonstrated severe tracheomalacia 
in the middle segment of the trachea, surprisingly situated 
not in the lower segment, close to the previous fistula (Fig. 2).
We decided to implant a PDS stent 5 × 25 mm, achiev-
ing dramatic resolution of the symptoms. The baby was 
extubated after the procedure and discharged home early. 
Subsequently, 2 other stents 1 mm larger in width were 
placed at intervals of 12–14 weeks with excellent tolerance. 
At present, the patient stays at home without respiratory 
problems. The baby is subject to follow-up bronchoscopy 
12 weeks after the last stent implantation with possible 
consecutive stent implantation.
Discussion
In the treatment of airway obstruction in small children, 
there are still no clearly defined indications for stenting 
and their use is considered individually for each patient.2,12 
Difficulty in  stenting is  related to  the  small diameter 
of the respiratory tract, to its growth and the possible need 
for stent replacement. The commonly used metal stents 
are considered by the majority of authors as “placed once 
and for good and bad” and potential replacement usually 
requires surgical intervention. In addition, the potential 
benefits of a particular stent group associated with their 
structure generate significant complications. For example, 
the risk of migration for metal stents is low, but their hard 
structure strongly impacts the mucosa, resulting in a high 
risk of granulation tissue formation and mucosal erosion 
with bleeding. On the other hand, softer plastic or silicone 
stents with a low rate of local complications present a con-
siderable tendency for migration.2
In order to avoid the abovedescribed complications, 
the attention of researches has been focused on biodegrad-
able materials. After encouraging experimental medical 
tests, the first bio-stents have been used with good results 
in adults after lung transplants.15 In the last 8 years, an in-
creasing number of reports addressing the use of bio-stents 
in children have been published.2,9–11,16 So far, PDS stents 
have been used mostly in the treatment of tracheal and 
bronchial compression after cardiovascular procedures,9 
after a failed aortopexy,10 after tracheoplasty due to con-
genital stenosis11 or in the cases of severe tracheo- and 
bronchomalacia.12,17,18
We  found the  offered polydioxanon self-expanding 
stents CS-ELLA very suitable for the use in pediatric pa-
tients. The mechanism of self-expansion and thus self-
fixing is one of the greatest advantages of PDS stents. It ex-
cludes the need for the balloon use to expand the stent 
and thereby reduces periods of full apnea. In our opinion, 
x-ray-controlled implantation with C-arm fluoroscopy 
is more logistically challenging and requires radiation, 
so we  decided in  favor of  implantation under general 
vision. We first inserted the  introducer with the stent 
to the bronchoscope 4.0 mm, having enough space to place 
laterally very thin optics (1.3 mm) longer than the bron-
choscope. After a partial withdrawal of the rigid broncho-
scope, at the critical area of the airway only the top part 
of the introducer was left along with thin optics with good 
visualization of the proximal stent border (Fig. 3A–D). 
Then, one of the operators withdrew the optics, the sec-
ond released the mechanism of the sheath sliding and 
opening the stent. This maneuver allowed for the reduc-
tion of the apnea time to a few seconds only and was well 
Fig. 1. Completely collapsed left main bronchus. Arrowhead points 
the place with stamp of the right main bronchus
Fig. 2. Severe tracheomalacia in the middle portion of the trachea
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tolerated by the patients after preoxygenation. It also al-
lowed us to abandon the C-arm fluoroscopy and offered 
more space and better comfort for the operative team. 
After 1 implantation, when the stent after expansion was 
located too distally, it was easy to relocate it upward using 
optical forceps. In both patients, the implanted stents kept 
the airway open with a round shape at the collapsing area 
without tendency for migration. Each stent maintained 
its integrity and hence stiffness for 12–15 weeks without 
noticeable morbidity.
A potential risk for the patient may be stent fragments 
in  the  final period of biodegradation that may narrow 
the airways.18 Thus, in every case, starting at 12 weeks 
after implantation, we checked the stent condition every 
2 weeks using bronchofiberoscopy.
In  the  treatment of  tracheobronchomalacia, airway 
stenting should be considered as a time-buying procedure. 
A low tendency to form mucosal granulation tissue, bio-
compability and the possibility of implanting another stent 
with the diameter adequate to the dimensions of the grow-
ing airway naturally favor bio-stents. But, on the other 
hand, a limiting factor can be the rather short time of com-
plete biodegredation and the need of frequent re-stenting.
Conclusions
Despite our limited experience with bio-stents, we con-
sider PDS stents an effective, safe, repeatable, and reversible 
option in the treatment of dynamic airway obstruction 
in  children. Further studies should be focused on  ex-
tending the “working time” of the bio-stents and reduc-
ing the thickness of stents and the size of  the surgical 
instruments.
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